Chu 2012.

Methods	Randomised controlled phase I/II study
Participants	14 ovarian cancer patients with complete clinical response to primary therapy (10 received treatment so far)
Interventions	Intradermal peptide pulsed dendritic cells (Her‐2/Neu, hTERT, PADRE): vaccine alone vs single dose of cyclophosphamide before first vaccination
Outcomes	Tumour responses Immune response Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Information about the sequence generation process insufficient to permit judgement of ‘low risk’ or ‘high risk’
Allocation concealment (selection bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of participants and personnel (performance bias) All outcomes	Low risk	No blinding or incomplete blinding, but review authors judge that the outcome is not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	High risk	Early termination due to financial limitations